HEPA News and Press, Hepion Pharmaceuticals Inc. From 06/23/20

Gainers:  Lilis Energy (NYSEMKT: LLEX ) +93% . More news on: Lilis Energy, Inc., Fuwei Films (Holdings) Co., Ltd., China Rapid Finance Limited, Stocks on the move, , Read more ...

Fuwei Films (NASDAQ: FFHL ) +66%  on Q1 results . More news on: Fuwei Films (Holdings) Co., Ltd., Translate Bio, Inc., Recon Technology, Ltd., Stocks on the move, , Read more ...

Nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) announces encouraging results from a Japan-based lab study evaluating lead candidate CRV431 in a mouse model of renal fibrosis (scarring). More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more...

Results Support CRV431's Potential to More Broadly Treat Fibrotic Diseases EDISON, NJ / ACCESSWIRE / June 22, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment ...

EDISON, NJ / ACCESSWIRE / June 10, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that Dr. Peter Wijngaard...

EDISON, NJ / ACCESSWIRE / May 20, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the advancement to th...

Dynavax Technologies (NASDAQ: DVAX ) +41%  as COVID-19 vaccine trial could start as soon as July. More news on: Dynavax Technologies Corporation, Arbutus Biopharma Corporation, cbdMD, Inc., Stocks on the move, , Read more ...

Hepion Pharmaceuticals (NASDAQ: HEPA ) has completed the submission of a Phase 1 data memo and the Phase 2a protocol to the FDA, and intends to commence its Phase 2a clinical trial of CRV431 for the treatment of NASH fibrosis in June. More news on: Hepion Pharmaceuticals, Inc., Healthcar...

- Results from Hepion's Phase 2a AMBITION Study Expected by Year-End 2020 - EDISON, NJ / ACCESSWIRE / May 19, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, "Hepion"), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +100% . More news on: Sonnet BioTherapeutics Holdings, Inc., MEI Pharma, Inc., NantKwest, Inc., Stocks on the move, Read more ...